U.S. Life Science & Diagnostic Tools: Read-throughs from Roche Dx Day

Research evidence excerpt

U.S. Life Science & Diagnostic Tools: Read-throughs from Roche Dx Day

Equity Research

U.S. Life Science & Diagnostic Tools

13 May 2026

Read-throughs from Roche Dx Day

No major Axelios updates other than targeting 100

placements this yr; TB IGRA launches in CE countries next

month + data at ESM Conf (June 22nd). Overall focus on U.S. Life Science & Diagnostic Tools POSITIVE

holistic approach to industry via digitization, AI, automation, U.S. Life Science & Diagnostic Tools

and gaining broader share vs. solely focusing on high-profile Luke Sergott

launches. +1 212 526 9258 luke.sergott@barclays.com

BCI, US

Roche (covered by James Gordon, read his recap note for a more comprehensive view here) Dx Salem Salem

sets the stage for the industry across central labs to POC testing and specialty LDT-based tests. +1 212 526 3431

The company emphasized that growth in the MT is being driven by focus on the highest-burden salem.salem@barclays.com

disease areas including oncology, neurology, cardiometabolic, and infectious BCI, US

disease. Diagnostics remains a core growth engine for the company with MSD-HSD LT growth Anna Kruszenski

expected, faster than the underlying market. This above market growth is underpinned by +1 212 526 0134

expansion into faster growing verticals such as sequencing, MRD, MCED, CGM, and decentralized anna.kruszenski@barclays.com

testing, alongside leverage from Roche’s installed base and global channel. Major product level BCI, US

drivers include Axelios ($1B blockbuster potential according to mgmt), Mass Spec, cobas Ultra Jacob Putman, CFA

automation, Smart e, IGRA TB, p‑tau217 testing for Alzheimer's, CGM, and AI-enabled digital +1 212 526 5704

pathology (PathAI), collectively positioning Roche to grow above market and extend its jacob.putman@barclays.com